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Duty to warnThe importance of genomic information for care of individual patients and for the development of knowledge
about treatment efﬁcacy is becoming increasingly apparent. This information is probabilistic and involves the
use of large data sets to increase the likelihood of detecting low frequency events. Duties and rights of patients
with respect to this information have been much discussed, including informed consent to the use of individual
information, privacy and conﬁdentiality, rights to know or not to know, and individual ownership of information
about themselves. But this is only one side of the information equation. On the other side of the equation are
duties of information holders: malpractice and duties to warn, responsibilities of data stewardship, intellectual
property and ownership, reciprocity, and justice. This article argues that if we take duties of patients to share
information seriously, we must also consider duties on the part of information holders about how they protect
and use information.
© 2014 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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ingly apparent (Institute of Medicine, 2012). Genomic information
may be helpful in assessing the likelihood and possible extent of thera-
peutic response, the possibility of treatment side effects, the risks of
drug–drug interactions in a particular patient, and the need to monitor
for disease prevention, among other factors. Much of the use of genomic
information is probabilistic at best—that is, information about a person's
genome, when combined with other information, is predictive but not
determinative of therapeutic outcomes. And genomic information hasen access article under the CC BY-NCone feature that at least some other forms of individually identiﬁable
health information do not: information about one individual may also
convey at least probabilistic information about their genetic relatives.
These features of genomic information raise many legal and ethical
issues.
Genomic information is initially information about a particular
individual's genetic or epigenetic makeup. Thus understood, it raises
problems of informed consent to the use of individual information, pri-
vacy and conﬁdentiality, rights to know or not to know, and ownership,
among other issues. Many of these issues have been much discussed
and are familiar.-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
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the probabilistic nature of much genomic information. Information
about an individual's genomic makeup, by itself, rarely yields deﬁnitive
diagnostic or prognostic information. Cases of the known signiﬁcance of
a single gene—such as the CAG repeats in the HTT gene on chromosome
4 present in Huntington's disease—are rare. Even in such cases, more-
over, some of what is known is probabilistic: the number of CAG
repeats, for example, is associatedwith age of disease onset. As genomic
medicine is developing today, large data sets establishing correlations
between particular genomic features are needed for understanding
the possible signiﬁcance of any individual's genomic characteristics.
This probabilistic nature of genetic information raises signiﬁcant ethical
and legal questions on the other side of the information equation: not
the patient side, but the information-holder side. These ethical and
legal issues, including malpractice and duties to warn, responsibilities
of data stewardship, intellectual property and ownership, reciprocity,
and justice are much less recognized but no less critical.
1. Genomic information about individuals
As pointed out above, much has been written about the ethical and
legal issues raised by genomic information about individuals. This
review presents a brief summary of these issues. Although the topics
are relatively familiar, understanding them is important both for patient
care and for appreciation of the ethical and legal problems on the other
side of the information equation. The import of genetic information
for individuals gives rise to reciprocal obligations, or so this article
contends.
1.1. Genetic information and identiﬁability
As a preliminary matter, several points about the individual
identiﬁability of genetic information are important to set out. The
presence of a particular genetic sequence does not, in the absence of
accompanying information, identify an individual. Under the HIPAA
privacy rule for the protection of individually identiﬁable health infor-
mation, genetic information does not contain any of the ﬁrst seventeen
factors listed for safe harbor de-identiﬁcation: patient's name, address,
telephone number, various dates, Social Security number and other
numbers identifying accounts, device serial numbers, photographic
images, biometric identiﬁers, and other similar identifying informa-
tion (Anon, 2014a). Only the ﬁnal listed factor for safe harbor de-
identiﬁcation applies directly to genomic information—“any other
unique identifying number, characteristic, or code”—in cases in which
genetic information is a unique identifying characteristic. By itself, a sin-
gle nucleotide polymorphism is not unique to a particular individual;
however, in combination with other publicly available information
about the individual genomic information may permit identiﬁcation
(Gymrek et al., 2013). Such risks of re-identiﬁcation depend on what
other information is publicly available; for example, Gymrek et al.
(Gymrek et al., 2013) used information in recreational genetic data-
bases and online search engines such as PeopleFinder to achieve re-
identiﬁcation. Importantly, these strategies can also be used to identify
individuals through information from very remote, unknown relatives.
1.2. Informed consent
When individuals provide information about themselves formedical
treatment, including for a genetic test, the parameters of informed con-
sent are relatively clear. Individuals can be told what uses of their infor-
mation are contemplated; standard notices of privacy practices inform
patients that their information may be used for treatment, payment,
or health care operations. For much information collected in treatment,
however, the possibility of future use in research has not been included
explicitly in any consent process, thus posing the question of the
permissibility of later research use. Because large sets of data maybe necessary to identify the signiﬁcance of low-frequency genomic
variants, this problem can be expected to persist. One work-around
has been to permit the research use of information that has been de-
identiﬁed or that has been stripped of sufﬁcient identiﬁers to qualify
as a HIPAA limited data set (Anon, 2014b).
Re-use of information originally collected in research raises related
issues. One recent study concludes that although almost 90% of partici-
pants in anNIH-funded genetics researchwerewilling to allow the sub-
mission of their data in de-identiﬁed form to dbGaP, the database of
genotypes and phenotypes at NIH (dbGaP, n. d), over two-thirds of
them also wanted the researchers to ask their permission (Ludman
et al., 2010).
As discussed above, genomic informationmay not be sufﬁciently de-
identiﬁable to facilitate the work-around of stripping out identiﬁers. To
allow the use of identiﬁable information in research, the Advanced
Notice of Proposed Rule-Making (ANPRM) for revisions to current
human subjects research protections published by HHS in 2011,
would allow general consent to any future use of data in research
(Anon, 2011). The ANPRM did, however, also suggests that especially
sensitive research such as stem cell research or research about repro-
duction might require more explicit consent. Genetic information,
because of its implications for others, may raise questions about the
need for explicit consent. At the same time, it may be difﬁcult to antici-
pate in advancewhat uses of genomic informationmight be desirable or
what their risks might be. If so, it will need to be argued that sufﬁciently
broad consent still may be informed consent (Sheehan, 2011).
The NIH Genomic Data Sharing Policy, issued August 27, 2014
(National Institutes of Health, 2014), requires all NIH-funded research
generating large-scale human (and non-human) genomic data to be
submitted to NIH. Data are to be de-identiﬁed in accord with the rules
governing research with human subjects and the HIPAA Privacy Rule.
For studies initiated, specimens collected, or cell lines created after the
effective date of the Policy, NIH expects investigators to obtain consent
for subsequent data use and broad data sharing. These consentsmust ex-
plain whether data will be shared through unrestricted or controlled-
access repositories. For studies, specimens, or cell lines antedating the
Policy, NIH requires investigators to consult with their IRB or relevant
privacy board to determine what sharing is consistent with consents
and to indicate any required limits when data are submitted to NIH.
The Policy's encouragement of consent to broad data sharing can be
expected to place additional pressure on the responsibilities of data-
holders discussed below.
1.3. Privacy and conﬁdentiality
Privacy protects individuals from unwarranted access to the person;
conﬁdentiality protects information about the person from unwanted
use or disclosure. Both have been thought to raise special issues regard-
ing genomic information. That genetic information about one person
can be used to infer information about genetic relatives poses the
privacy-like concern that informationmay be gleaned about individuals
without direct access to them or even their knowledge. In part because
of what may be exaggerated beliefs about its predictive power, genetic
information has also been thought to be especially risky. These concerns
led to the federal statute giving special protection from discrimination
on the basis of genetic information in employment and health insur-
ance, the Genetic Information Non-Discrimination Act (Prince and
Berkman, 2012).
Such genetic exceptionalism may be unwarranted, however
(Rothstein, 2008). Other health information—such as diagnoses of infec-
tious diseases—may be at least as and potentially more risky and
stigmatizing than genetic information. Although genetic information
may seem unique in its possible implications for relatives, other health
information such as a household member's exposure to toxins may
also reveal information about relatives. That there is reason to question
genetic exceptionalism, however, does not abate the potential risks to
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that these risks may be more widespread (Rothstein, 2008).
1.4. Rights to know and not to know
As a principle of bioethics, respect for autonomy means that people
may have opt to refuse as well as to consent to medical procedures or
treatment, even if this would be unwise. So, individuals may choose
not to undergo diagnostic interventions, including genomic sequencing.
So-called “incidental” genomic ﬁndings—ﬁndings revealed by planned
techniques for genomic analysis but not the immediate subject of
diagnostic concern—present particular challenges for patient choice.
TheAmerican College ofMedical Genetics andGenomics recently issued
guidelines for the release of incidental ﬁndings in certain cases of
clinical signiﬁcance (ACMG, n. d). Discussing these guidelines, McGuire
et al. argue that informed consent requires explanation to patients that
genomic sequencing may reveal incidental ﬁndings, that the choice of
analytical techniques and clinical relevance is a matter of expert clinical
judgment, but that “in rare cases” clinicians and appropriately informed
patients may decide not to follow recommendations regarding disclo-
sure of incidental ﬁndings (McGuire et al., 2013).
Such exercise of autonomy raises ethical questions when it has
implications for others. Rhodes (Rhodes, 1998) argued that duties to
others require people to allow their genetic information to be shared
both with relatives for whom it might have clinical signiﬁcance and
for population studies that might advance medical knowledge. Rhodes'
argument is directed towards data that has been or could be obtained
in clinical care; the NIH Genomic Data Sharing Policy urges sharing of
data gained in research (National Institutes of Health, 2014). Rhodes'
argument rests on views aboutmutual responsibilities: of commitment,
of friendship, and of common humanity. If there are such duties of
reciprocity on the part of patients, this article contends below, they
extend to the other side of the information equation as well.
1.5. Data ownership
Ownership of patient information and tissue samples is a matter for
state law. The general view is that patients do not own their information
or tissue samples. Alaska, however, provides that DNA samples and the
results of DNA tests are the “exclusive property” of the person analyzed
(Anon, 2014c). Oregon had a similar statute but it was repealed in 2001
(History of Oregon's Genetic Privacy Law, n. d). The Alaska statute poses
an ethical dilemma for genetic testing laboratories: can they continue to
use information concerning patients in Alaska to analyze the signiﬁ-
cance of variants? If they cannot do so, what are their responsibilities
to tested patients to inform them of new ﬁndings about the signiﬁcance
of variants—for example, that a variant of previously unknown signiﬁ-
cance has now been identiﬁed with disease risks? Arguably good pa-
tient care requires providing updated information about new ﬁndings
of signiﬁcance, but the fact that Alaska patients' data could not be
used to generate the ﬁndings suggests that they are free riding (albeit
unintentionally) on the use of data from others. Questions of fairness
raised here extend not only to other patients providing the beneﬁt of
their data but also to laboratories incurring costs of determining when
and how itmight be appropriate to convey information about new ﬁnd-
ings of signiﬁcance. That other patients' data are being used to beneﬁt
everyone receiving tests is an important social good but also points to
the need to consider ethical responsibilities of the data holder.
1.6. Summary
Concerns about genomic information have resulted in some special
legal protections. Nonetheless, the prevailing ethical view is that
patients have an obligation to share genomic information with relatives
for whom it might be clinically useful. Arguments have also been made
for individuals' obligations to allow genomic information, clinical records,and tissue samples to be included indatabases that are needed to improve
understanding of the signiﬁcance of variants. These arguments are
accompanied by the values of informed consent and respect for patient
autonomy. They also highlight the importance of understanding of the
potential risks of genetic information. The arguments for sharing informa-
tion are also complemented, this article contends, by obligations on the
information holder's side of the information equation.
2. Responsibilities of information holders
Genomic information is not only information about individuals; it is
increasingly sets of “big data” that can be analyzed to develop knowl-
edge about the signiﬁcance of individual genomic variations. Some of
these databases are maintained as resources for the public good. For ex-
ample, dbGaP, the database of genotypes and phenotypes (dbGaP, n. d),
requested NIH-funded researchers to submit data from genome wide
association studies. As of August 2014, it had resulted in 924 publica-
tions listed in PubMed, many in top-ranked journals (Paltoo et al.,
2014). As of January, 2015, the NIH Genomic Data Sharing Policy will
be in effect, applying to all NIH-funded research generating large-scale
human and non-human genomic data and the use of this data in subse-
quent research (National Institutes of Health, 2014). The Policy will
require investigators to whom it applies to submit data to NIH so that
it can be used in subsequent research (National Institutes of Health,
2014) and can be expected to broaden the utility of this data extensive-
ly. MutaDATABASE is a collection of genomic sequencing data from a
consortium of European, Asian, Australian, and US laboratories (Bale
et al., 2011). Many other databases are proprietary: the vast resources
of patient clinical information possessed by large health care systems,
laboratories offering genetic testing, or health insurers, for example.
Other genetic information that may also be used commercially exists
outside of the clinical realm, as individuals seek to learn about their
ancestry, ﬁnd relatives, or assess disease risk. That this information
lies outside the clinical realm was recently underscored when the
Food and Drug Administration issued a warning letter to 23andMe,
claiming that the company was marketing a genetic test without
obtaining proper market clearance (23andMe, Inc., n. d). Nonetheless
23andMe and other companies continue to collect samples to provide
people with information about their likely ancestral origins.
While some legal issues involving information holders are quite well
developed, others are not and still others arguably have developed in
ways that are problematic from an ethical point of view. These ethical
and legal issues, including malpractice and the duty to warn, responsi-
bilities of data stewardship, intellectual property and ownership,
reciprocity, and justice are as noted above much less recognized but
no less important than the obligations of individuals.
2.1. Malpractice and duties to warn
It is malpractice when providers' failure tomeet the standard of care
causes harm to their patients. Genomic information is no different in
this regard (Downs and Trias, 2012), although as medical knowledge
is rapidly evolving what standards of care require may be in ﬂux as
well. Most of the litigated cases about genetic information have in-
volved potential parents who were not informed about the availability
or results of genetic tests to determine risks of inherited diseases such
as cystic ﬁbrosis or TaySachs disease and who then had affected chil-
dren. A few cases have also considered whether providers have legal
duties to warn family members of known genetic disease risks; these
cases divide on whether there is such a duty and whether it can be
discharged by informing their patients of the importance of sharing
the information with their family members. Although the law has not
developed a great deal in the area of genetic information, it is surely
arguable that health care providers have ethical duties to inform their
patients of known genetic risks and to consider with their patients the
likely importance of this information to family members.
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The seminal statement of basic principles of data stewardship was
made by the then-US Department of Health Education and Welfare in
1973 (Department of Health, Education, and Welfare, 1973). Records,
Computers, and the Rights of Citizens urged transparency and openness,
purpose speciﬁcation, data integrity, and data security as core fair infor-
mation practices. This report applied to computerized records held in
both the public and the private spheres; the federal Privacy Act in
which it resulted, however, created legal obligations only for the federal
government. Many subsequent data stewardship proposals continue to
urge more general application of these principles (NCVHS, 2009).
Although discussions of data stewardship have evolved (NCVHS,
2009), these principles remain core. Holders of databases of genomic
and phenotypic information have these stewardship responsibilities.
This means that there should be no secrecy about data collection and
use. It means that purposes of data use should be speciﬁed and that de-
viations from stated purposes are inappropriate without opportunities
for consent. Thus it would be unethical to use a database assembled to
improve understanding of the signiﬁcance of genomic variants to
improve underwriting of health insurance premiums. The principle of
purpose speciﬁcation also comes into play when data acquired in
clinical care are used to advance the commercial interests of health
care providers—unless these intended purposes were speciﬁed in ad-
vance. Data integrity includes protecting data from corruption and
employing good practices to assure accuracy. Data security includes
protecting data from unintended access or use as well as maintaining
the physical security of data.
These principles of data stewardship are ethical principles. Actual
legal requirements are far more limited. Most important are the US
federal HIPAA Security Rule and Privacy Rule (Anon, 2014d). These
requirements are limited to protected health information, however,
and do not apply to data collected by recreational genetic companies
or other private sector entities outside of the context of health care. Im-
portantly, once data have been de-identiﬁed they are no longer subject
to HIPAA protection. Also, once data have been transferred from a
HIPAA-covered entity to a non-HIPAA covered entity, they are no longer
protected under HIPAA. Many of the large genomic databases thus are
outside of the sphere of HIPAA protection.
A second framework of legal protection in theUS is the Federal Trade
Commission Act forbidding unfair or deceptive trade practices (Federal
Trade Commission Act, 2014). Stating one purpose for data use and then
putting the data to a different use—a data bait and switch—is a deceptive
trade practice. It is also an unfair trade practice to subject data to unrea-
sonable risks that consumers could not adequately protect against, as
when retailers fail to institute appropriate security measures to protect
against credit card theft. Arguably, failure to maintain adequate data-
base security that allowed hackers to access identiﬁable health informa-
tion would be an unfair trade practice, even when the data are not
HIPAA-protected.
2.3. Intellectual property
Entities possessing databases of health information or developing
methods for analyzing them may have intellectual property rights in
these assets. These rights may be of three kinds: patents, copyrights,
or trade secrets. The general justiﬁcation for intellectual property rights
is creating economic incentives for discovery, innovation, and creation;
the concern about these rights is that their assertionmay deprive others
of access to important knowledge or products (Bitton, 2006; Lyndon,
2007; Zufelt and Robert Rehm, 2011). This justiﬁcatory balance has
been applied to create quite different legal regimes for the different
types of intellectual property rights. As the lawhas developed, however,
these regimes are not always well alignedwith patients' interests in the
development of genomic knowledge that might prove clinically beneﬁ-
cial to them.US patent law is federal (indeed, constitutionally established); by
statute, patents may be obtained on processes, machines, manufactures
or compositions of matter that are new. There are exceptions for prod-
ucts or laws of nature, physical phenomena, or abstract ideas; these
should be free for all to use. In its recent decision involving Myriad
Genetics' patent claims to genes implicated in the development of
breast and ovarian cancer (Association for Molecular Pathology and
Myriad Genetics, 2013), the United States Supreme Court invalidated
patents on naturally occurring genetic sequences but upheld the patent-
ability of created cDNA. The case was unusual because it concerned the
very patentability of genetic sequences under Section 1 of the Patent
Act. An important feature of patent law is that it grants exclusive rights
in exchange for the disclosure of the invention. Thus others interested in
research in the area of a patentmay know about the intellectual proper-
ty and seek rights to use it from the patent holder. Awareness of the
intellectual property may also be useful to others working in the area
to build upon it or otherwise gain from knowledge of its subject matter.
Nonetheless, assertion of patent rights can be a signiﬁcant bar to devel-
oping knowledge, if patent-holders refuse to grant licenses or charge
prohibitive amounts for these licenses. The NIH Genomic Data Sharing
Policy, while recognizing the legitimacy of patent rights, also empha-
sizes that naturally occurringDNA sequences—including basic sequence
data and related information—are not patentable; the Policy also en-
courages broad use of NIH-funded genomic data and discourages the
use of patents to prevent the use of data developed with NIH support
(National Institutes of Health, 2014). This encouragement is directed
to patent rights, however, and not to other formsof intellectual property
that may also become roadblocks to data sharing.
Copyright law (also constitutional and federal) protects “creations.”
Ideas themselves, concepts in the work, or information gathered from
elsewhere are not copyrightable, unless there is creation. “Compilations”
in the sense of works “formed by the collection and assembling of
preexisting materials or of data that are selected, coordinated, or
arranged in such a way that the resulting work as a whole constitutes
an original work of authorship,” (Anon, 2014e) are copyrightable. Mere
re-compilations such as telephone book listing numbers are not, however
(Feist Publications, Inc. and Rural Telephone Services Co., 1991). Thus
compendia of clinical information would not be copyrightable absent
some novelty in themethod of arrangement, expression, or presentation.
In addition, computer programs may be copyright-able as works of au-
thorship, so programs for organizing databases are copyrightable. Analyt-
ic methods such as algorithms for detecting disease incidence, however,
would need to be considered under patent law. An important difference
between copyright and patent law is that applications for copyright regis-
tration do not require disclosure of the actual work. So an information
holder could seek to register copyright in a database by naming the
compilation but would not be required to disclose the data themselves.
Trade secret law is amatter of the commercial laws of the individual
states, although there is a great deal of uniformity as most states have
adopted provisions of the Uniform Trade Secrets Act. The purpose of
trade secrets law is to allow businesses to protect items of economic im-
portance to them. To assert a trade secret, a business must take appro-
priate steps not to reveal it. Trade secrets do not require invention or
creation; they require protection. Increasingly, private sector entities
possessing databases are asserting trade secrets protection for them. It
is estimated, for example, that Myriad Genetics has a major advantage
over other entities offering genetic testing because of the data it has ob-
tained about possible phenotypic signiﬁcance of variants (Cook-Deegan
et al., 2013). Particularly problematic features of trade secrets law are
the lack of external validation of results and the indeﬁnite time period
of protection (Cook-Deegan et al., 2013; Institute of Medicine, 2012).
The US Institute of Medicine (Institute of Medicine, 2012) has recom-
mended that all funders of genomic translational research require
“investigators to make all data, metadata, prespeciﬁed analysis plans,
computer code, and fully speciﬁed computational procedures publicly
available and readily interpretable…” (Institute of Medicine, 2012, p. 3).
125L.P. Francis / Applied & Translational Genomics 3 (2014) 111–1152.4. Reciprocity and justice
As outlined in the ﬁrst section of this article, individuals who allow
their data to be used for the development of genomic knowledge take
risks that enable others to beneﬁt. Ethical obligations of reciprocity sug-
gest that they should receive something in return: arguably the appro-
priate exercise of responsibilities on the part of the information holder
discussed in the preceding sections. If information holders fail to protect
information appropriately or put information to unanticipated uses,
they have failed in their responsibilities as data stewards as discussed
above. But reciprocity and justice require more as well.
Information holders of large data sets drawn from clinical informa-
tion possess a very valuable resource for the development of knowledge
about patient care. When people have conferred a beneﬁt on others for
the good of thewhole, reciprocity suggests they should receive in return
the opportunity to beneﬁt from that good. For purposes of this article
about information sharing, this means at a minimum that scientiﬁc
developments obtained from large-scale genomic databases should be
publicly available. If genomic databases are used only for private
commercial ends, reciprocity in this sense will not be recognized.
Reciprocity will also not be recognized if the assertion of intellectual
property rights prevents the use of the database for the overall good,
and instead turns it only to private gain, as may well be occurring
with the developing use of trade secrets law.
In addition, some contemporary approaches to genomic data raise
questions of justice. If information gathered from some is put to the
beneﬁt of others—particularly to the beneﬁt of those who are more
privileged—injustice may result. Because of the expense and compara-
tive unavailability of genomic sequencing for many, the information
currently available in at least some databases may be skewed towards
the more privileged (Cook-Deegan et al., 2013). This places increased
importance on sharing information so that lower frequency events can
be detected even in less-well-represented populations. Cook-Deegan
et al. make the point powerfully about the extent to which genomic in-
formation is skewed globally towards the better-off (Cook-Deegan et al.,
2013). Insistence on proprietary rights over genomic information thus
may have untoward consequences for justice.
2.5. Summary
Holders of genomic information thus have ethical obligations that
mirror the importance of the resource that they possess. These obligations
may include avoidingmalpractice and considering the use of information
to alert others to clear risks, data stewardship, reciprocity, and justice.
These ethical obligations are not well served by some aspects of current
law, especially in the area of intellectual property.
3. Conclusion
Genomic information is increasingly important to patients and their
families. Although this information is notwithout risks, individuals haveethical obligations to allow this information to be used for the common
good. But they should have the opportunity to know how information is
being shared and used and they should be protected against risks of
disclosure. Information holders thus have responsibilities of data stew-
ardship. They also have ethical responsibilities to use this valuable
resource to the beneﬁt of individuals at risk and for the common good,
in a manner that is just.
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